

CORRECTION

# Correction: Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue

**Fabian Jacob, Amina Y. Yonis, Friederike Cuello, Pradeep Luther, Thomas Schulze, Alexandra Eder, Thomas Streichert, Ingra Mannhardt, Marc N. Hirt, Sebastian Schaaf, Justus Stenzig, Thomas Force, Thomas Eschenhagen, Arne Hansen**

The toxic threshold concentration (TTC,  $\mu\text{M}$ ) values for Sunitinib and Imatinib are swapped in [Fig 1B](#). The toxic threshold concentration for Sunitinib is 1.88  $\mu\text{M}$  and the toxic threshold concentration for Imatinib is 18.99  $\mu\text{M}$ . The safety margin (TTC/TPC) values for Sunitinib and Imatinib are also incorrect. The correct safety margin for Sunitinib is 9.4 and the correct safety margin for Imatinib is 9.4. Please see the correct [Fig 1](#) here.




**OPEN ACCESS**

**Citation:** Jacob F, Yonis AY, Cuello F, Luther P, Schulze T, Eder A, et al. (2018) Correction: Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. PLoS ONE 13(11): e0208342. <https://doi.org/10.1371/journal.pone.0208342>

**Published:** November 27, 2018

**Copyright:** © 2018 Jacob et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



B.

	Therapeutic plasma concentration (TPC, $\mu\text{M}$ )	Toxic threshold concentration (TTC, $\mu\text{M}$ )	Safety margin (TTC/TPC)
<b>Erlotinib</b>	2.5 $\mu\text{M}$ <sup>1</sup>	n/a	n/a
<b>Dasatinib</b>	0.04 $\mu\text{M}$ <sup>2</sup>	n/a	n/a
<b>Gefitinib</b>	0.116 $\mu\text{M}$ <sup>3</sup>	6.29 $\mu\text{M}$	54
<b>Lapatinib</b>	1.1 $\mu\text{M}$ <sup>5</sup>	31.38 $\mu\text{M}$	29
<b>Sunitinib</b>	0.2 $\mu\text{M}$ <sup>4</sup>	1.88 $\mu\text{M}$	9.4
<b>Imatinib</b>	2.02 $\mu\text{M}$ <sup>6</sup>	18.99 $\mu\text{M}$	9.4
<b>Sorafenib</b>	6.5 $\mu\text{M}$ <sup>9</sup>	12.71 $\mu\text{M}$	2.0
<b>Vandetanib</b>	2.1 $\mu\text{M}$ <sup>7</sup>	2.08 $\mu\text{M}$	1
<b>Lestaurtinib</b>	7.7 $\mu\text{M}$ <sup>8</sup>	0.28 $\mu\text{M}$	0.04

**Fig 1. TKI effect on EHT contractility.** (A) Depiction of concentration-effect curves (curve-fitted) of 9 TKIs after 96 hours of TKI incubation (▲), normalized to vehicle control (Δ). The toxic threshold (black dashed line) is defined as a decline in contractile force of >40% vs. baseline (BL). Mean values  $\pm$  SEM; n = 4; \*p<0.05 vs. baseline, two-way ANOVA and Bonferroni's multiple comparison post-test. (B) Total therapeutic plasma concentration (TPC), toxic threshold concentration (TTC: TKI concentration leading to  $\geq$ 40% reduction in EHT contractile force) and safety margin (SM: TTC/TPC), n/a: not applicable.

<https://doi.org/10.1371/journal.pone.0208342.g001>

The toxic threshold concentration and safety margin values for Sunitinib and Imatinib are also incorrect in [S1 Table](#). Please see the correct [S1 Table](#) below.

## Supporting information

**S1 Table. Summary TKI pharmacology and EHT effects on contractility.**  
(DOCX)

## Reference

1. Jacob F, Yonis AY, Cuello F, Luther P, Schulze T, Eder A, et al. (2016) Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue. PLoS ONE 11(2): e0145937. <https://doi.org/10.1371/journal.pone.0145937> PMID: 26840448